急性细菌性皮肤和皮肤结构感染疾病市场规模（按感染类型、药物类型、给药途径、分销管道、区域覆盖范围和预测）

急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）的市场规模和预测

急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场规模在 2024 年价值 114.9 亿美元，预计到 2032 年将达到 239.4 亿美元，2026 年至 2032 年的复合年增长率为 9.6%。

急性细菌性皮肤及皮肤结构感染疾病(ABSSSI) 是指皮肤及皮下软组织的严重细菌感染疾病，必须立即使用抗生素治疗。这类感染包括蜂窝组织炎组织炎、丹毒、严重皮肤脓疡和伤口感染。

腹腔镜皮肤感染 (ABSSSI) 通常由革兰氏阳性菌引起，尤其是葡萄球菌，例如抗药性金黄色葡萄球菌(MRSA) 和链球菌。如果没有有效治疗，这些感染疾病可能导致严重的併发症，症状包括患处发红、肿胀、不适和发热。

全球急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场动态

影响急性细菌性皮肤和皮肤结构感染疾病市场的关键市场动态是：

关键市场驱动因素

皮肤和软组织感染疾病盛行率不断上升：皮肤和软组织感染疾病（尤其是非小细胞肺癌感染，ABSSSI）的盛行率不断上升，是推动该市场发展的主要动力。根据美国疾病管制与预防中心 (CDC) 的数据，2015美国美国约有 1,420 万人次因皮肤和软组织感染疾病就诊。如此高的盛行率凸显了改进 ABSSSI治疗方法的迫切需求。

抗生素抗药性日益加剧：人们对抗生素抗药性细菌日益增长的担忧，正在推动针对ABSSSIs的新治疗方法的开发。根据世界卫生组织 (WHO) 的数据，抗生素抗药性病菌感染在2019年造成超过120万人死亡。这种令人担忧的状况正在推动对ABSSSIs新药和新治疗方案的需求。

医疗保健支出不断增长：全球医疗保健支出的不断增长正在推动ABSSSIs市场的发展。根据世界银行的数据，全球医疗保健支出占GDP的比重从2000年的8.5%上升到2019年的9.8%。医疗保健投资的不断增加正在改善ABSSSIs等疾病的治疗方法可近性，尤其是在富裕国家。

主要挑战

开发成本高：研发新的ABSSSI药物和治疗方法需要大量的研发投入。该技术成本高昂，阻碍了製药公司在该领域的投资，限制了产品的可用性和创新。

治疗方案有限：儘管对有效ABSSSI治疗的需求日益增长，但核准的治疗药物却寥寥无几。缺乏便捷的治疗方案限制了患者的选择，阻碍了市场的快速成长。

抗生素抗药性：抗生素抗药性细菌日益普遍，导致急性腹腔感染 (ABSSSI) 难以有效治疗。这降低了现有抗生素的有效性，同时也增加了对创新治疗方案的需求，而这些方案的开发既困难又耗时。

主要趋势

提高认识和盛行率：由于皮肤和软组织感染疾病的增加，特别是在免疫力缺乏的患者和患有慢性疾病的患者中，人们对 ABSSSI 的盛行率和发病率不断上升的认识不断提高，从而推动了市场的发展。

治疗方法的进步：诊断和治疗技术的进步正在改变ABSSSI市场。先进的影像技术和快速诊断检测有助于早期发现，从而及时介入并改善患者预后。

製药公司越来越注重研发：製药公司越来越注重研发，包括开发针对抗生素抗药性菌株的新型药物和治疗方法，以满足以前未满足的医疗需求。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

4. 急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场（依感染类型）

• 医院获得性 ABSSSI
• 社区型 ABSSSI

5. 急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场（依药物类型）

• 口服抗生素
• 局部抗生素

6. 急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场（依给药途径）

• 口服
• 肠外给药
• 局部的

7. 急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场（依分销管道）

• 医院药房
• 零售药局
• 网路药局
• 其他的

第八章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第九章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第十章 竞争格局

• 主要企业
• 市场占有率分析

第十一章 公司简介

• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd
• Bayer AG
• GlaxoSmithKline plc
• Sanofi SA
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics, Inc.

第十二章 市场展望市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十三章 附录

• 简称列表
• 来源和参考文献

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Size and Forecast

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market size was valued at USD 11.49 Billion in 2024 and is projected to reach USD 23.94 Billion by 2032, growing at a CAGR of 9.6% from 2026 to 2032.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are severe bacterial infections of the skin and underlying soft tissues that must be treated immediately with antibiotics. They include cellulitis, erysipelas, severe cutaneous abscesses, and wound infections.

ABSSSIs are typically caused by Gram-positive bacteria, particularly Staphylococcus and Streptococcus species, such as methicillin-resistant Staphylococcus aureus (MRSA). If not treated effectively, these infections can cause severe morbidity, with symptoms including redness, swelling, discomfort, and warmth at the affected site.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Dynamics

The key market dynamics that are shaping the acute bacterial skin and skin structure infection market include:

Key Market Drivers

Increasing Prevalence of Skin and Soft Tissue Infections: The increased frequency of skin and soft tissue infections, especially ABSSSIs, is a major driver of this market. According to the US Centers for Disease Control and Prevention (CDC), there were approximately 14.2 million outpatient consultations for skin and soft tissue infections in the United States in 2015. This high prevalence highlights the urgent need for improved therapies for ABSSSI.

Rising Antibiotic Resistance: The growing concern about antibiotic-resistant bacteria is pushing the development of new treatments for ABSSSI. According to the World Health Organization (WHO), antibiotic-resistant bacterial infections killed more than 1.2 million people in 2019. This concerning development is driving the need for new medicines and treatment options for ABSSSIs.

Increasing Healthcare Expenditure: The global increase in healthcare spending is boosting the ABSSSI market. According to the World Bank, worldwide health expenditure as a proportion of GDP increased from 8.5% in 2000 to 9.8% in 2019. This increased healthcare investment is improving access to therapies for illnesses such as ABSSSIs, especially in wealthy countries.

Key Challenges:

High Development Costs: Significant research and development investments are required to create novel ABSSSI medicines and therapies. The high costs of this technique deter pharmaceutical companies from investing in this field, restricting product availability and innovation.

Limited Treatment Options: Despite the increasing demand for effective ABSSSI treatments, there are just a few authorized medications available. The scarcity of accessible treatment choices limits patient options and inhibits the market from growing as quickly as it can.

Antibiotic Resistance: Antibiotic-resistant bacterial strains are becoming increasingly common, making it difficult to treat ABSSSIs effectively. This diminishes the efficacy of current antibiotics while increasing the demand for innovative therapeutic options, which are difficult and time-consuming to develop.

Key Trends:

Growing Awareness and Prevalence: The market is being driven by increased awareness of the prevalence of ABSSSI, as well as rising incidence rates. This trend is caused by an increase in skin and soft tissue infections, particularly among immunocompromised people and those suffering from chronic conditions.

Advancements in Treatment Options: Technological advances in diagnoses and treatment techniques are transforming the ABSSSIs market. Advanced imaging techniques and speedy diagnostic tests promote early detection, resulting in timely interventions and better patient outcomes.

R&D Initiatives by Pharmaceutical Companies: Pharmaceutical companies are increasingly focusing on R&D. This includes the creation of novel medications and therapy targeted to antibiotic-resistant strains, thereby meeting previously unmet medical requirements.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Regional Analysis

Here is a more detailed regional analysis of the acute bacterial skin and skin structure infection market:

North America:

According to Verified Market Research, North America is estimated to dominate the acute bacterial skin and skin structure infection market over the forecast period. Skin and soft tissue infections, including ABSSSIs, are common in North America, especially in the United States. In 2014, the United States Centers for Disease Control and Prevention (CDC) reported roughly 3.4 million emergency department visits for skin and soft tissue infections. This high prevalence increases the demand for ABSSSI therapies in the region.

North America has a well-developed healthcare system and high healthcare spending, which allows for improved detection and treatment of ABSSSIs. According to the Centers for Medicare and Medicaid Services, healthcare spending in the United States increased by 4.6% in 2019, to USD 3.8 Trillion, or $11,582 per person. This level of spending encourages the use of newer, more effective therapies for ABSSSI.

Furthermore, MRSA is a common cause of ABSSSIs, and its presence in North America serves as a substantial market driver. The CDC estimates that approximately 2% of the population has MRSA. In 2017, there were around 323,700 cases of MRSA in hospitalized patients in the United States. This high occurrence of antibiotic-resistant illnesses necessitates the development of sophisticated ABSSSI treatments in the region.

Europe:

Europe region is estimated to exhibit substantial growth during the forecast period. Europe has a high incidence of skin and soft tissue infections, particularly ABSSSIs. According to the European Centre for Disease Prevention and Control (ECDC), surgical site infections, a kind of ABSSSI, were reported in 3.2% of surgical procedures in Europe in 2019. This high prevalence increases the demand for effective therapies in the region.

The increasing prevalence of antibiotic-resistant bacteria in Europe is driving the discovery and implementation of innovative treatments for ABSSSIs. According to the ECDC, over 33,000 persons in the EU/EEA died as a result of antibiotic-resistant bacterial illnesses in 2019. Methicillin-resistant Staphylococcus aureus (MRSA), a prevalent cause of ABSSSIs, is still a major public health concern, with MRSA accounting for more than 25% of Staphylococcus aureus isolates in seven of the 29 countries studied.

Furthermore, the aging of Europe's population, as well as the rise of chronic diseases, help to drive the ABSSSI market forward. According to Eurostat, the proportion of people aged 65 and up in the EU is expected to rise from 20.3% in 2019 to 29.4% in 2050. ABSSSIs are more likely to affect older persons and those with chronic diseases such as diabetes. According to the International Diabetes Federation, 59 million adults in Europe had diabetes in 2019, and this figure is anticipated to climb to 68 million by 2045, thereby increasing the incidence of ABSSSIs.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia Pacific region has a large population, which naturally results in a higher incidence of ABSSSI cases. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's population is predicted to increase from 4.3 billion in 2020 to 4.7 billion in 2050. This population increase translates to a larger patient pool for ABSSSIs, which drives market growth.

Diabetes poses a considerable risk for skin infections, especially ABSSSIs. According to the International Diabetes Federation (IDF), the number of adults living with diabetes in the Western Pacific region (which includes much of Asia) is anticipated to rise from 163 million in 2019 to 212 million by 2045. The rising prevalence of diabetes is anticipated to contribute to an increased incidence of ABSSSIs in the region.

Furthermore, the Asia Pacific region is rapidly improving its healthcare infrastructure and access. According to the World Health Organization (WHO), health expenditure as a proportion of GDP in Southeast Asia rose from 3.5% in 2000 to 4.4% in 2017. Improved healthcare spending and infrastructure development are improving diagnostic and treatment capabilities for illnesses such as ABSSSIs, resulting in market growth.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market: Segmentation Analysis

The Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market is segmented based on Infection Type, Drug Type, Route of Administration, Distribution Channel, and Geography.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Infection Type

• Hospital-acquired ABSSSI
• Community-acquired ABSSSI

Based on Infection Type, the market is segmented into Hospital-acquired ABSSSI and Community-acquired ABSSSI. The hospital-acquired ABSSSI segment is estimated to dominate the acute bacterial skin and skin structure infection market due to the high incidence of hospital-acquired ABSSSI cases caused by variables such as impaired skin integrity, the presence of multi-drug resistance organisms in healthcare settings, and immunosuppressed patients' susceptibility to severe infections.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Drug Type

• Oral & Parental Antibiotics
• Topical Antibiotics

Based on Drug Type, the market is segmented into Oral & Parental Antibiotics and Parental Antibiotics. The oral & parental antibiotics segment is estimated to dominate the acute bacterial skin and skin structure infection market during the forecast period owing to their great efficiency against a wide spectrum of bacterial illnesses and convenience of administration via the oral route. Parenteral antibiotics are especially important in severe cases because they provide increased bioavailability and tissue penetration, which is critical for treating illnesses such as bacteremia and sepsis.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Route of Administration

• Oral
• Parental
• Topical

Based on the Route of Administration, the market is segmented into Oral, Parental, and Topical. The parental segment is estimated to dominate the acute bacterial skin and skin structure infection market because parenteral antibiotics can quickly enter the bloodstream and successfully battle severe ABSSSI cases. The parenteral method is preferable for its quick drug administration and tailored treatment approach, particularly in urgent ABSSSI cases requiring prompt action.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Based on the Distribution Channel, the market is segmented into Hospital, Retail, Online, and Others. The hospital pharmacies segment is estimated to dominate the acute bacterial skin and skin structure infection market. Hospital pharmacies play an important role in ABSSSI therapy because they provide prompt access to essential medicines and work closely with healthcare teams to develop antibiotic regimens. Furthermore, hospital pharmacies help patients make a smooth transition to outpatient care by giving drugs upon release, assuring thorough and efficient ABSSSI therapy.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the acute bacterial skin and skin structure infection market is classified into North America, Europe, Asia Pacific, and the Rest of the World. According to the VMR analyst, North America is estimated to dominate during the forecasted period due to leading pharmaceutical companies' substantial research operations, a focus on creating anti-MRSA medications, and the introduction of new products. North America's market revenue is predicted to remain dominant due to the region's robust healthcare infrastructure and widespread awareness of ABSSSIs.

Key Players

• The "Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Inc., Merck & Co., Inc., AstraZeneca plc, Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Paratek Pharmaceuticals, Inc., and Melinta Therapeutics, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Acute Bacterial Skin and Skin Structure Infection Market Recent Developments
• In July 2021, Melinta Therapeutics, a pharmaceutical firm, released KIMYRSA, as a lipoglycopeptide antibiotic efficacious for treating acute bacterial skin and skin structure infections (ABSSSI) in a single 1200mg injectable dose.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Type of Infection

• Hospital-acquired ABSSSI
• Community-acquired ABSSSI

5. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Drug Type

• Oral & Parenteral Antibiotics
• Topical Antibiotics

6. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Route of Administration

• Oral
• Parenteral
• Topical

7. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

8. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

9. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

10. Competitive Landscape

• Key Players
• Market Share Analysis

11. Company Profiles

• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd
• Bayer AG
• GlaxoSmithKline plc
• Sanofi S.A.
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics, Inc.

12. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

13. Appendix

• List of Abbreviations
• Sources and References